Skip to content
Homepage
Author:
Vascarta Inc
Posted Date:
June 24, 2026
Vascarta Announces Phase I Results of VAS-101 Administered Sublingually in Sickle Cell Disease Patients
Vascarta Inc
June 24, 2026
Vascarta Announces Addition of Richard Serbin to Leadership Team
Vascarta Inc
June 9, 2026
Vascarta Announces Positive Clinical Trial Results for Topical/Transdermal Curcumin Gel VAS-101 in Knee Osteoarthritis
Vascarta Inc
April 1, 2026
